NCT05289492View on ClinicalTrials.gov

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

November 29, 2023

Study Completion Date

November 29, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

EOS884448

EOS884448 will be administered in arm A,B and C

DRUG

Iberdomide

Iberdomide will be administered in arm B and C

DRUG

Dexamethasone

Dexamethasone will be administered in arm C

Trial Locations (13)

1070

Institut Jules Bordet, Brussels

2020

ZNA Cadix, Antwerp

3000

Universitaire Ziekenhuizen KU Leuven, Leuven

28040

Hospital Fundacion Jimenez Diaz, Madrid

31059

CHU Toulouse, Toulouse

44093

Centre Hospitalier Universitaire de Nantes, Nantes

75012

APHP Hôpital Saint-Antoine, Paris

80054

CHU Amiens, Amiens

85234

Banner MD Anderson, Gilbert

86021

CHU de Poitiers, Poitiers

98109

Fred Hutchinson Cancer Center, Seattle

06360

Eastern Connecticut Hematology & Oncology, Norwich

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

iTeos Therapeutics
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

iTeos Belgium SA

INDUSTRY

lead

iTeos Therapeutics

INDUSTRY

NCT05289492 - Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter